Dupixent COPD denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for COPD as Not FDA-Approved

A not-FDA-approved denial — sometimes labeled "off-label use" — means UnitedHealthcare determined that dupilumab is not approved by the FDA for the specific indication as documented in your claim. This type of denial requires careful scrutiny: the FDA did grant dupilumab approval for a defined COPD population, so if your prescriber's documentation clearly places you within that approved indication, the denial may reflect a coding issue, a policy that has not been updated since approval, or a mismatch between how the claim was coded and the approved indication language.

If your use genuinely falls outside the approved indication (true off-label), the appeal path is different but still viable, as many insurers cover off-label use supported by recognized compendium listings or guideline organizations.

## Federal Appeal Rights

• ACA §2719 requires external independent review for clinical denials, including coverage determinations based on medical or scientific evidence — this squarely covers not-FDA-approved / off-label disputes.
• ERISA §503 guarantees full-and-fair internal review with written denial reasoning.
• Internal appeal: typically 180 days from denial notice.
• External review: typically 4 months from final internal denial.
• Expedited review available when delay would seriously jeopardize your health.

## Step 1: Determine Whether This Is Actually Off-Label

Before drafting your appeal, obtain the current FDA-approved prescribing label for dupilumab (available at FDA.gov) and compare the indication language to how your prescriber documented your diagnosis. If your chart documentation and claim coding align with the approved indication, this is a documentation or coding correction issue, not a clinical dispute.

## What to Gather

1. Current FDA prescribing label — print the full approved indication section for COPD. Highlight the patient population criteria and the mechanism-of-action language. 2. Diagnosis documentation — chart notes confirming COPD and the clinical characteristics that place you within the FDA-approved population (type-2 inflammatory markers, exacerbation history, lung function documentation). 3. Claim coding review — ask your prescriber's office to confirm that the diagnosis and procedure codes submitted match the FDA-approved indication. 4. Prescriber medical-necessity letter — should explicitly state that the prescribed use is within the FDA-approved indication, cite the label, and reference the applicable guideline organization (e.g., GOLD, relevant pulmonology society) that supports this use. 5. UHC's current coverage policy for dupilumab — compare the policy effective date to the FDA approval date; if the policy predates approval, note this discrepancy explicitly.

## Criteria-Mapping Structure

| Denial Basis | Response | |---|---| | Use is off-label / not FDA-approved | Cite FDA approval date, indication text from label, and patient's chart alignment | | Claim coding mismatch | Confirm ICD/NDC codes match approved indication; resubmit if needed | | Policy predates FDA action | Note policy date vs. approval date; request updated policy application |

If the use is genuinely off-label, additionally request any applicable recognized drug compendium listings (e.g., NCCN, Micromedex, or equivalent) that support the use — many UHC plans cover off-label use supported by recognized compendia. Your prescriber should address this in their letter.